Celltrion, Inc.

KOSE:A068270 Stock Report

Market Cap: ₩39.3t

Celltrion Past Earnings Performance

Past criteria checks 4/6

Celltrion's earnings have been declining at an average annual rate of -5.3%, while the Biotechs industry saw earnings growing at 18.2% annually. Revenues have been growing at an average rate of 15.4% per year. Celltrion's return on equity is 2.9%, and it has net margins of 13.1%.

Key information

-5.32%

Earnings growth rate

-10.59%

EPS growth rate

Biotechs Industry Growth11.70%
Revenue growth rate15.45%
Return on equity2.95%
Net Margin13.13%
Last Earnings Update30 Jun 2025

Recent past performance updates

Celltrion's (KRX:068270) Weak Earnings May Only Reveal A Part Of The Whole Picture

Nov 22
Celltrion's (KRX:068270) Weak Earnings May Only Reveal A Part Of The Whole Picture

Recent updates

Investors Interested In Celltrion, Inc.'s (KRX:068270) Earnings

Sep 30
Investors Interested In Celltrion, Inc.'s (KRX:068270) Earnings

Celltrion (KRX:068270) Takes On Some Risk With Its Use Of Debt

May 03
Celltrion (KRX:068270) Takes On Some Risk With Its Use Of Debt

Celltrion, Inc.'s (KRX:068270) Popularity With Investors Is Clear

Apr 09
Celltrion, Inc.'s (KRX:068270) Popularity With Investors Is Clear

Estimating The Intrinsic Value Of Celltrion, Inc. (KRX:068270)

Jan 06
Estimating The Intrinsic Value Of Celltrion, Inc. (KRX:068270)

Is Celltrion (KRX:068270) A Risky Investment?

Dec 10
Is Celltrion (KRX:068270) A Risky Investment?

Celltrion's (KRX:068270) Weak Earnings May Only Reveal A Part Of The Whole Picture

Nov 22
Celltrion's (KRX:068270) Weak Earnings May Only Reveal A Part Of The Whole Picture

Revenue & Expenses Breakdown

How Celltrion makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSE:A068270 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 253,748,951492,078758,920199,719
31 Mar 253,662,235508,918752,981199,719
31 Dec 243,557,304422,692750,762199,719
30 Sep 242,876,253187,097759,641161,112
30 Jun 242,666,611323,331606,655161,112
31 Mar 242,315,848392,826404,491161,112
31 Dec 232,176,432535,648195,001161,112
30 Sep 232,304,473603,795196,472139,714
30 Jun 232,277,818542,616179,966139,714
31 Mar 232,350,070582,780183,631139,714
31 Dec 222,283,967526,616204,971139,714
30 Sep 222,376,733566,168220,603125,769
30 Jun 222,133,015543,369217,022125,769
31 Mar 221,967,894482,930194,374125,769
31 Dec 211,893,401569,488180,730125,769
30 Sep 211,788,695564,777175,444171,437
30 Jun 211,935,547597,615167,273171,437
31 Mar 211,933,237608,477150,937171,437
31 Dec 201,849,116517,760126,626171,437
30 Sep 201,733,144512,182148,229113,568
30 Jun 201,473,428402,929140,896113,568
31 Mar 201,279,603342,041141,114113,568
31 Dec 191,128,460301,030131,592113,568
30 Sep 19988,284230,443144,915108,060
30 Jun 19930,333225,180131,754108,060
31 Mar 19958,797228,480126,670108,060
31 Dec 18982,075245,755113,897108,060
30 Sep 181,013,790308,254132,37579,660
30 Jun 181,014,774355,009131,87479,660
31 Mar 18997,483381,655125,61279,660
31 Dec 17949,080368,222112,70179,660
30 Sep 17883,631308,46194,72787,856
30 Jun 17819,814263,66678,50587,856
31 Mar 17758,701215,81265,77887,856
31 Dec 16670,581158,95875,51787,856
30 Sep 16630,045176,69996,72237,320
30 Jun 16631,225181,01588,83537,320
31 Mar 16614,243179,60584,30637,320
31 Dec 15603,413154,09066,69637,320
30 Sep 15534,991117,38944,62069,642
30 Jun 15470,68270,14452,55169,642
31 Mar 15481,79784,08366,04069,642
31 Dec 14471,046112,67664,76769,642

Quality Earnings: A068270 has high quality earnings.

Growing Profit Margin: A068270's current net profit margins (13.1%) are higher than last year (12.1%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A068270's earnings have declined by 5.3% per year over the past 5 years.

Accelerating Growth: A068270's earnings growth over the past year (52.2%) exceeds its 5-year average (-5.3% per year).

Earnings vs Industry: A068270 earnings growth over the past year (52.2%) exceeded the Biotechs industry 35.5%.

Return on Equity

High ROE: A068270's Return on Equity (2.9%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/10/22 23:46
End of Day Share Price 2025/10/22 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Celltrion, Inc. is covered by 38 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Girish BakhruBofA Global Research
Dae Woong YooBookook Securities Co. Ltd
Hyeryeong KimCGS International